1461092378-e4bf08b9-f19c-44dc-b715-20d5e8ec17d5

What is claimed is:

1. A method for determining whether TAXOL can be used to reduce the growth of a tumor, comprising the steps of:
a) obtaining a sample of tumor cells;
b) determining whether the tumor cells express one or more sensitivity markers identified in Tables 1 and 3; and
c) identifying that TAXOL can be used to reduce the growth of the tumor cells when the one or more sensitivity markers are expressed.
2. The method of claim 1, wherein the level of expression is determined by detecting the amount of mRNA that is encoded by the one or more markers present in the sample.
3. The method of claim 1, wherein the level of expression is determined by detecting the amount of protein that is encoded by said one or more markers present in the sample.
4. The method of claim 1, wherein said tumor cells are obtained from a tumor cell line or a tumor obtained from a subject.
5. A method for determining whether TAXOL cannot be used to reduce the growth of a tumor, comprising the steps of:
a) obtaining a sample of tumor cells;
b) determining whether the tumor cells express one or more markers selected from the group consisting of the sensitivity markers identified in Tables 1 and 3; and
c) identifying that TAXOL cannot be used to reduce the growth of the tumor when one or more of the sensitivity markers in Tables 1 and 3 is not expressed or is underexpressed by the tumor cells
6. The method of claim 5, wherein the level of expression is determined by detecting the amount of mRNA that is encoded by the one or more sensitivity markers present in the sample.
7. The method of claim 5, wherein the level of expression is determined by detecting the amount of protein that is encoded by said one or more markers present in the sample.
8. The method of claim 5, wherein said tumor cells are obtained from a tumor cell line or a tumor obtained from a subject.
9. A method for determining whether TAXOL can be used to reduce the growth of a tumor, cancer cells, comprising the steps of:
a) obtaining a sample of tumor cells;
b) determining whether the tumor cells express one or more markers selected from the group consisting of the resistance markers in Tables 2 and 4; and
c) identifying that TAXOL can be used to reduce the growth of the tumor when one or more of the resistance markers in Tables 2 and 4 is not expressed or is underexpressed by the tumor cells.
10. The method of claim 9, wherein the level of expression is determined by detecting the amount of mRNA that is encoded by the one or more markers present in the sample.
11. The method of claim 9, wherein the level of expression is determined by detecting the amount of protein that is encoded by said one or more markers present in the sample.
12. The method of claim 9, wherein said tumor cells are obtained from a tumor cell line or a tumor obtained from a subject.
13. A method for determining whether TAXOL cannot be used to reduce the growth of a tumor, comprising the steps of:
a) obtaining a sample of tumor cells;
b) determining whether the tumor cells express one or more markers selected from the group consisting of the resistance markers identified in Tables 2 and 4; and
c) identifying that TAXOL cannot be used to reduce the growth of the tumor when one or more of the markers in Tables 2 and 4 is expressed or overexpressed by the cancer cells.
14. The method of claim 13, wherein the level of expression is determined by detecting the amount of mRNA that is encoded by the one or more markers present in the sample.
15. The method of claim 13, wherein the level of expression is determined by detecting the amount of protein that is encoded by said one or more markers present in the sample.
16. The method of claim 13, wherein the tumor cells are obtained from a tumor cell line or a tumor obtained from a subject.
17. A method for determining whether TAXOL can be used to reduce the growth of a tumor, comprising the steps of:
a) obtaining a sample of tumor cells;
b) exposing the tumor cells to TAXOL;
c) determining the level of expression in the tumor cells of one or more markers selected from the group consisting of the sensitivity markers identified in Tables 1 and 3 in the sample exposed to TAXOL and in a sample of tumor cells that is not exposed to TAXOL; and
d) identifying that TAXOL can be used to reduce the growth of said tumor when the expression of one or more of said markers is increased in the presence of TAXOL.
18. The method of claim 17, wherein the level of expression is determined by detecting the amount of mRNA that is encoded by the one or more markers present in the sample.
19. The method of claim 17, wherein the level of expression is determined by detecting the amount of protein that is encoded by said one or more markers present in the sample.
20. The method of claim 17, wherein the tumor cells are obtained from a tumor cell line or a tumor obtained from a subject.
21. A method for determining whether TAXOL cannot be used to reduce the growth of tumor cells, comprising the steps of:
a) obtaining a sample of tumor cells;
b) exposing the tumor cells to TAXOL;
c) determining the level of expression in the tumor cells of one or more markers selected from the group consisting of the sensitivity markers identified in Tables 1 and 3 in the sample exposed to TAXOL and in a sample of tumor cells that is not exposed to TAXOL; and
d) identifying that TAXOL cannot be used to reduce the growth of the tumor when the expression of one or more of said markers is not increased in the presence of TAXOL.
22. The method of claim 21, wherein the level of expression is determined by detecting the amount of mRNA that is encoded by the one or more markers present in the sample.
23. The method of claim 21, wherein the level of expression is determined by detecting the amount of protein that is encoded by said one or more markers present in the sample.
24. The method of claim 21, wherein the tumor cells are obtained from a tumor cell line or a tumor obtained from a subject.
25. A method for determining whether TAXOL can be used to reduce the growth of a tumor, comprising the steps of:
a) obtaining a sample of tumor cells;
b) exposing the tumor cells to TAXOL;
c) determining the level of expression in the tumor cells of one or more markers selected from the group consisting of the resistance markers identified in Tables 2 and 4 in the sample exposed to TAXOL and in a sample of tumor cells that is not exposed to TAXOL; and
d) identifying that TAXOL can be used to reduce the growth of the tumor when the expression of one or more of said markers is not increased in the presence of TAXOL.
26. The method of claim 25, wherein the level of expression is determined by detecting the amount of mRNA that is encoded by the one or more markers present in the sample.
27. The method of claim 25, wherein the level of expression is determined by detecting the amount of protein that is encoded by said one or more markers present in the sample.
28. The method of claim 25, wherein the tumor cells are obtained from a tumor cell line or a tumor obtained from a subject.
29. A method for determining whether TAXOL cannot be used to reduce the growth of a tumor, comprising the steps of:
a) obtaining a sample of tumor cells;
b) exposing the tumor cells to TAXOL;
c) determining the level of expression in the tumor cells of one or more markers selected from the group consisting of the resistance markers identified in Tables 2 and 4 in the sample exposed to TAXOL and in a sample of tumor cells that is not exposed to TAXOL; and
d) identifying that TAXOL cannot be used to reduce the growth of the tumor when the expression of one or more of said markers is increased in the presence of TAXOL.
30. The method of claim 29, wherein the level of expression is determined by detecting the amount of mRNA that is encoded by the one or more markers present in the sample.
31. The method of claim 29, wherein the level of expression is determined by detecting the amount of protein that is encoded by said one or more markers present in the sample.
32. The method of claim 29, wherein the tumor cells are obtained from a tumor cell lines or a tumor obtained from a subject.
33. A method for determining whether treatment with TAXOL should be continued in a cancer patient, comprising the steps of:
a) obtaining two or more samples comprising cancer cells from a patient during the course of treatment;
b) determining the level of expression in the cancer cells of one or more markers selected from the group consisting of the sensitivity markers identified in Tables 1 and 3 in the two or more samples; and
c) continuing treatment when the expression level of one or more of the markers does not decrease during the course of treatment.
34. The method of claim 33, wherein the level of expression is determined by detecting the amount of mRNA that is encoded by the one or more markers present in the sample.
35. The method of claim 33, wherein the level of expression is determined by detecting the amount of protein that is encoded by said one or more markers present in the sample.
36. A method for determining whether treatment with TAXOL should be discontinued in a cancer patient, comprising the steps of:
a) obtaining two or more samples comprising cancer cells from a patient during the course of treatment;
b) determining the level of expression in the cancer cells of one or more markers selected from the group consisting of the sensitivity markers identified in Tables 1 and 3 in the two or more samples; and
c) discontinuing treatment when the expression level of one or more of the markers decreases during the course of treatment.
37. The method of claim 36, wherein the level of expression is determined by detecting the amount of mRNA that is encoded by the one or more markers present in the sample.
38. The method of claim 36, wherein the level of expression is determined by detecting the amount of protein that is encoded by said one or more markers present in the sample.
39. A method for determining whether treatment with TAXOL should be discontinued in a cancer patient, comprising the steps of:
a) obtaining two or more samples comprising cancer cells from a patient during the course of treatment;
b) determining the level of expression in the cancer cells of one or more markers selected from the group consisting of the resistance markers identified in Tables 2 and 4 in the two or more samples; and
c) discontinuing treatment when the expression level of one or more of the markers does not decrease during the course of treatment.
40. The method of claim 39, wherein the level of expression is determined by detecting the amount of mRNA that is encoded by the one or more markers present in the sample.
41. The method of claim 39, wherein the level of expression is determined by detecting the amount of protein that is encoded by said one or more markers present in the sample.
42. A method for determining whether treatment with TAXOL should be continued in a cancer patient, comprising the steps of:
a) obtaining two or more samples comprising cancer cells from a patient during the course of treatment;
b) determining the level of expression in the cancer cells of one or more markers selected from the group consisting of the resistance markers identified in Tables 2 and 4 in the two or more samples; and
c) continuing treatment when the expression level of one or more of the markers does not increase during the course of treatment.
43. The method of claim 42, wherein the level of expression is determined by detecting the amount of mRNA that is encoded by the one or more markers present in the sample.
44. The method of claim 42, wherein the level of expression is determined by detecting the amount of protein that is encoded by said one or more markers present in the sample.
45. An isolated nucleic acid molecule comprising a nucleotide sequence of SEQ ID NOS:1-88.
46. A vector which contains the nucleic acid molecule of claim 45.
47. A host cell which contains the nucleic acid molecule of claim 45.
48. An isolated polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence of SEQ ID NOS:1-88.
49. An antibody which selectively binds to a polypeptide of claim 48.
50. A method for producing a polypeptide comprising culturing the host cell of claim 47 under conditions in which the nucleic acid molecule is expressed.
51. A method for detecting the presence of a polypeptide of claim 48 in a sample comprising:
a) contacting the sample with a compound which selectively binds to the polypeptide; and
b) determining whether the compound binds to the polypeptide in the sample to thereby detect the presence of a polypeptide of claim 48 in the sample.
52. A kit comprising a compound which selectively binds to the polypeptide of claim 48.
53. A method for detecting the presence of a nucleic acid molecule of claim 45 in a sample comprising:
a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and
b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample to thereby detect the presence of a nucleic acid molecule of claim 45 in the sample.
54. The method of claim 53, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.
55. The method of claim 53, wherein the sample is isolated from ovarian tissue.
56. The method of claim 53, wherein the sample is a tumor sample.
57. A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of claim 45.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A lithographic apparatus comprising:
an illumination system configured to condition a radiation beam;
a support constructed to support a patterning device, the patterning device being capable of imparting the radiation beam with a pattern in its cross-section to form a patterned radiation beam;
a substrate table constructed to hold a substrate;
a projection system configured to project the patterned radiation beam onto a target portion of the substrate; and
an oscillation device configured to impart a controlled oscillation perpendicular to an optical axis of the projection system to at least one of the patterning device support and the substrate table.
2. A lithographic apparatus according to claim 1, wherein the controlled oscillation has a timing such that a period of the controlled oscillation is less than an exposure time of the target portion of the substrate.
3. A lithographic apparatus according to claim 2, wherein the controlled oscillation has a period of less than half of a duration of an exposure of the target portion of the substrate.
4. A lithographic apparatus according to claim 1, wherein:
the substrate table is configured to move according to a motion profile such that the patterned radiation beam is projected at intervals along the motion profile with respect to the substrate surface; and
the oscillation device is configured to superimpose the controlled oscillation onto the substrate table motion profile.
5. A lithographic apparatus according to claim 1, wherein the oscillation device is configured to oscillate the patterned radiation beam relative to the substrate.
6. A lithographic apparatus according to claim 1, wherein the illumination system includes a radiation source and is configured to provide the radiation beam in pulses, the pulses being at the same frequency as the controlled oscillation imparted by the oscillation device.
7. A lithographic apparatus according to claim 6, wherein the oscillation device is configured to impart an oscillation with a sinusoidal behavior, and if the sinusoidal behavior is considered to have an equal amplitude on either side of a zero-axis, the illumination system is configured to time the pulse of the radiation beam such that the radiation beam is projected onto the substrate substantially during a crossing of the zero-axis by the controlled oscillation.
8. A lithographic apparatus according to claim 1, wherein the oscillation device is configured to impart a controlled oscillation with an amplitude in the range of from 2 to 10 times the amplitude of a maximum substrate table control error.
9. A lithographic apparatus according to claim 1, wherein the oscillation device is configured to impart a controlled oscillation with an amplitude in the range of from 20 to 100 nm.
10. A lithographic apparatus according to claim 1, wherein the oscillation device comprises an actuator configured to oscillate at a predetermined frequency at least one of the patterning device support and the substrate table.
11. A lithographic apparatus according to claim 1, further comprising a relative position detector for detecting a relative position of the patterned radiation beam and the substrate.
12. A lithographic apparatus according to claim 11, wherein the relative position detector comprises: an individual position detector for at least one of each of the patterning device support, the substrate table and the optical element; and a processor for calculating a relative error between each of the individual position detector outputs.
13. A lithographic apparatus according to claim 11, wherein the relative position detector is configured to transmit information regarding the relative position of the patterned radiation beam and the substrate to the illumination system, and the illumination system is configured to cause the timing of a pulsing of the radiation beam to coincide with the alignment of the patterned radiation beam and the substrate.
14. A lithographic apparatus according to claim 1, wherein the substrate table is constructed to oscillate at a timing such that the radiation beam pulses onto the substrate at a timing in the middle of an oscillation of the substrate table, when the added oscillation crosses a zero-axis, the zero-axis being defined as an axis about which the amplitude of sinusoidal oscillation is equal.
15. A lithographic apparatus according to claim 1, wherein the oscillation device is configured to cause a controlled oscillation at a frequency of approximately 4 kHz.
16. A lithographic apparatus according to claim 1, wherein the oscillation device is configured to cause controlled oscillation in either an x-direction in the plane of the substrate, a y-direction in the plane of the substrate, or in a vectorial combination of both the x- and y-directions.
17. A lithographic apparatus comprising:
an illumination system configured to condition a radiation beam;
a support constructed to support a patterning device, the patterning device being capable of imparting the radiation beam with a pattern in its cross-section to form a patterned radiation beam;
a substrate table constructed to hold a substrate;
a projection system configured to project the patterned radiation beam onto a target portion of the substrate; and
a relative position detector configured to detect a relative position between the patterned radiation beam and the target portion of the substrate,
wherein the illumination system is further configured to impart a timed pulse to the radiation beam, the pulse being timed to coincide with a minimal positional offset between the patterned radiation beam and the target portion of the substrate.
18. An optical device for use in a projection apparatus configured to project a patterned radiation beam onto a substrate, the optical device being configured to cause oscillation of the patterned radiation beam relative to the substrate in a direction perpendicular to an optical axis of the projection system.
19. A method of projecting a patterned radiation beam onto a substrate comprising imparting a controlled relative oscillatory motion between the projected patterned radiation beam and the substrate, the relative oscillatory motion being in a direction perpendicular to a direction of projection of the projected patterned radiation beam.
20. A method according to claim 19, wherein the frequency of the oscillation is the substantially the same as a frequency of a pulsing of the projected patterned radiation beam.
21. A method according to claim 19, wherein a pulse of the patterned radiation beam is synchronized with a timing in the controlled relative oscillatory motion in which the relative velocity of the patterned radiation beam and the substrate is substantially constant.
22. A device manufacturing method comprising projecting a patterned beam of radiation onto a substrate, and oscillating an image of the patterned radiation beam with respect to a substrate on which the patterned radiation beam is projected in a direction perpendicular to a projection direction of the patterned beam of radiation.
23. (canceled)